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OBJECTIVES This study was designed to evaluate the effects of low-dose enoximone on exercise capacity.
BACKGROUND At higher doses the phosphodiesterase inhibitor, enoximone, has been shown to increase
exercise capacity and decrease symptoms in heart failure patients but also to increase
mortality. The effects of lower doses of enoximone on exercise capacity and adverse events
have not been evaluated.
METHODS This is a prospective, double-blind, placebo-controlled, multicenter trial (nine U.S. centers)
conducted in 105 patients with New York Heart Association class II to III, ischemic or
nonischemic chronic heart failure (CHF). Patients were randomized to placebo or enoximone
at 25 or 50 mg orally three times a day. Treadmill maximal exercise testing was done at
baseline and after 4, 8 and 12 weeks of treatment, using a modified Naughton protocol.
Patients were also evaluated for changes in quality of life and for increased arrhythmias by
Holter monitoring.
RESULTS By the protocol-specified method of statistical analysis (the last observation carried-forward
method), enoximone at 50 mg three times a day improved exercise capacity by 117 s at 12
weeks (p 5 0.003). Enoximone at 25 mg three times a day also improved exercise capacity at
12 weeks by 115 s (p 5 0.013). No increases in ventricular arrhythmias were noted. There
were four deaths in the placebo group and 2 and 0 deaths in the enoximone 25 mg three times
a day and enoximone 50 mg three times a day groups, respectively. Effects on degree of
dyspnea and patient and physician assessments of clinical status favored the enoximone
groups.
CONCLUSIONS Twelve weeks of treatment with low-dose enoximone improves exercise capacity in patients
with CHF, without increasing adverse events. (J Am Coll Cardiol 2000;36:501–8) © 2000
by the American College of Cardiology
Although effective therapy with angiotensin-converting en-
zyme inhibitors (ACEIs) and beta-adrenergic blocking
agents is now available for patients with mild-to-moderate
class II to III heart failure, therapy for individuals with more
advanced heart failure is less certain. Subjects with advanced
heart failure are, by definition, severely impaired function-
ally and usually have a poor quality of life. Standard therapy
with beta-blockers (1) and even ACEIs (2) may not be
well-tolerated in patients with advanced heart failure, re-
quiring inotropic therapy or cardiac transplantation in
acceptable candidates. Unfortunately, heart transplantation
is not an option for the majority of patients with end stage
heart disease, because of age and donor supply limitations.
Additionally, treatment of mild-to-moderate heart failure
patients with the beta-blockers that can be tolerated im-
proves survival substantially but has little or no effect on
exercise capacity or quality of life (3). These observations
indicate that medical treatment for chronic heart failure
(CHF) needs improvement.
Enoximone is an imidazolone derivative that selectively
inhibits sarcoplasmic reticulum-associated type III phos-
phodiesterase, which is expressed at high levels in human
ventricular myocardium and vasculature (4–6). Myocardial
and vascular phosphodiesterase inhibition (PDEI) increases
cAMP levels, respectively activating protein kinase A and G
to produce positive inotropic and vasodilator responses
(4–9). Enoximone’s inotropic effects are additive with
beta-blockers in vitro and in vivo (4). This additive effect
means that enoximone and other PDEIs can partially
restore the attenuation in myocardial beta-receptor signal
transduction (coupled with chronotropic and inotropic re-
sponses) that characterizes the failing human heart (9–11).
Another way in which enoximone could improve exercise
responses is by preferentially increasing skeletal muscle
blood flow (12). In contrast with beta-blockers, enoximone
improves myocardial function without an increase in myo-
cardial oxygen demand (13), and long-term administration
of enoximone is not accompanied by beta-adrenergic recep-
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tor desensitization phenomena (14) or tolerance to effects
on exercise capacity (15). Thus, oral enoximone is an agent
that can potentially be used to increase exercise capacity
and/or quality of life in CHF, as shown in previously
reported placebo-controlled trials (16,17).
Unfortunately, enoximone used at the higher doses
(4 – 6 mg/kg/day) that were originally tested in CHF
increased mortality (18). However, enoximone at doses
of #3.0 mg/kg/day has been used successfully as a bridge
to heart transplant without an apparent increase in
mortality (16). The purpose of this study was to evaluate
the effects of lower doses (1–2 mg/kg/day) of enoximone
on exercise capacity and adverse events in a placebo-
controlled setting.
METHODS
Patient selection. This study was conducted at nine heart
failure centers in the U.S. patients with symptomatic, New
York Heart Association (NYHA) class II to III heart failure
between the ages of 18 and 80 years of age and with left
ventricular ejection fractions #45% were enrolled. The
study was conducted with the approval of the local ethics
committee and with written, informed consent signed by
each patient.
Study protocol. This was a multicenter, placebo-
controlled, double-blind trial in patients with CHF. Enoxi-
mone at 25 (E25) or 50 mg three times a day (E50) was
compared with placebo in 105 patients. The primary end
point was maximal exercise duration, with various measures
of symptoms as secondary end points, assessed by intention-
to-treat. The exercise testing protocol consisted of a multi-
stage modified Naughton (19). At baseline, subjects had to
be able to exercise for 3 min and for no more than 16 min.
Baseline exercise tests were repeated every 10 to 14 days
until they were within 15% of each other, at which point the
last two tests were averaged to obtain the Time 0 baseline
value. If after three tests the exercise duration was not
within 15% of the prior two, the average of the last two tests
was used as the Time 0 baseline. Patients underwent
follow-up exercise tests at 4, 8 and 12 weeks after random-
ization.
The primary end point of this study was the effect on
maximum exercise capacity as assessed by treadmill exercise
time at 12 weeks analyzed by the last observation carry-
forward method. Secondary end points included adverse
events, quality of life and arrhythmias between the treat-
ment and placebo groups.
Concurrent therapy with digoxin, diuretics and sublingual
nitroglycerin was allowed. Patients were excluded if they were
receiving vasodilators (nitrates, ACEIs, hydralazine or prazo-
sin) or beta-blockers that could not be safely stopped. Women
of childbearing potential and patients with recent (,3 months)
myocardial infarction were also excluded from the study.
Patients with stenotic valvular disease, restrictive or hypertro-
phic cardiomyopathy or uncontrolled atrial fibrillation (mean
heart rate . 110) were also excluded.
After a baseline medical stabilization period of 10 to 42
days, patients were randomized to placebo or to one of the
two doses of enoximone. Clinical response was assessed by
patient and physician investigator’s overall evaluations of
improvement (“Global Assessment Instrument”) compared
with baseline, and symptoms were assessed by the investi-
gator’s determination of the NYHA classification as well as
by a four-tier (none, mild, moderate, severe) dyspnea scale.
In a subset of patients, Holter monitoring was performed at
baseline, four weeks and 12 weeks.
Statistical analysis. Statistical analysis of exercise data
(intent-to-treat) was evaluated in two ways. One data set
was drawn from all subjects who completed each time point
(“time course” analysis). The second used the “last observa-
tion carried forward” (LOCF) method by imputing missing
values from the last available measurement available after
baseline testing. The LOCF was the protocol-specified
method of primary end point analysis of the exercise data.
The between-group statistical methodology used was re-
peated measures analysis of variance (ANOVA), with spe-
cific comparisons between groups being made by using
linear contrasts (20). This method compares each dose with
placebo (between-group analysis) and each time point with
baseline (between-time analysis). In addition, within-group
analyses by repeated-measures ANOVA were done for all
groups (time-response analysis) and for all times (dose-
response analysis). Finally, repeated measures ANOVA was
used to assess dose-time response.
Global assessment data were analyzed by comparing the
number of subjects who were rated as improved or worsened
to subjects in the other two categories in the enoximone
groups versus the placebo group. The Global assessment
instrument has five rank ordered categories, which were
collapsed into three for purposes of data analysis. Data
analysis at 4, 8 and 12 weeks was as described for the
time-course method for exercise data. New York Heart
Association and dyspnea scale data were analyzed by deter-
mining the number of subjects who improved or worsened
by $1 class, with the statistical methodology as for the
time-course method for exercise tolerance.
Holter monitor data were analyzed by comparing changes
from baseline 24-h recordings within and between the three
treatment groups using nonparametric methods due to
skewed distributions. The three Holter parameters analyzed
Abbreviations and Acronyms
ACEI 5 angiotensin-converting enzyme inhibitor
AE 5 adverse event
ANOVA 5 analysis of variance
CHF 5 chronic heart failure
LOCF 5 last observed carry forward
NYHA 5 New York Heart Association
PDEI 5 phosphodiesterase inhibitor
PVC 5 premature ventricular contraction
VT 5 ventricular tachycardia
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were average heart rate, premature ventricular contraction
(PVCs)/h and ventricular tachycardia (VT) events/h. Ad-
verse event data were compared among the three groups by
contingency table analysis using Fisher’s Exact Test.
Hospitalizations were retrospectively tabulated from ad-
verse event data reports and compared among the three
treatment groups by contingency table analysis.
RESULTS
Baseline demographic data. Of the 105 patients enrolled,
20, 24 and 25 patients completed the study in the placebo,
E25 and E50 groups, respectively. The baseline character-
istics of the patients evaluated in this study are presented in
Table 1. There were no statistically significant baseline
differences among the three groups.
Maximal exercise tolerance. Exercise time data are given
in Figures 1 and 2.
Time-course analysis. The within-group analysis of the
“time-course” data in Figure 1 indicated a significant im-
provement (p , 0.05) compared with baseline in the
placebo group at eight weeks, the E25 group at eight and 12
weeks and the E50 group at four, eight and 12 weeks. All
three groups had a progressive significant improvement in
exercise duration incorporating all four time points into the
within-group analysis (time-response analysis), with
changes in the enoximone groups being significant at p ,
0.0001 and the placebo group at p , 0.05.
In the between-group analysis, the E50 group was
significantly increased at four weeks compared with the
placebo group, and the E25 and E50 groups were at
statistical significance at 12 weeks (respective p values of
0.050 and 0.051). On dose-response analysis, the four-
week data were statistically significant (p , 0.05), and
the 8- (p 5 0.18) and 12-week (p 5 0.057) data exhibited
trends. Compared with the placebo group, the time-
response relationship trended towards significance for
both the E25 (p 5 0.14) and E50 (p 5 0.073) groups.
The dose-time response analysis of all doses and time
points was nearly significant in favor of increasing re-
sponse with ascending dose (p 5 0.079).
LOCF analysis. The protocol-specified method of ana-
lyzing the primary end point was the between group analysis
of exercise duration at 12 weeks, using the LOCF tech-
nique. These data are presented in Figure 2. The E25 group
Figure 1. Time Course Analysis.
Table 1. Baseline Demographic and Clinical Characteristics (mean 6 SEM)
Demographics
Placebo
(n 5 35)
E25
(n 5 33)
E50
(n 5 37)
Age (yrs) 58.6 6 1.6 57.9 6 2.0 62.0 6 1.3
Sex (M/F) 29/6 24/9 27/10
Weight (kg) 80.1 6 3.1 77.0 6 3.0 73.3 6 2.2
NYHA (I/II/III/IV) 0/15/20/0 1/18/14/0 0/17/20/0
LVEF 21 6 4 25 6 4 23 6 4
Dyspnea score (0/1/2/3) 5/10/19/1 1/14/14/4 1/15/18/2
Duration of CHF (month) 46 6 10 36 6 6 37 6 7
Etiology (ischemic/nonischemic, n) 23/12 17/16 19/18
Cardiomegaly on CXR (n) 24 24 24
Medications (n, [%]):
Diuretics 34 (97) 31 (94) 33 (89)
Cardiac glycosides 29 (83) 29 (83) 29 (78)
Antianginal agents 1 (3) 0 (0) 0 (0)
Dyspnea Score: 0 5 none, 1 5 mild, 2 5 moderate, 3 5 severe.
CHF 5 chronic heart failure; CXR 5 chest X-ray; LVEF 5 left ventricular ejection fraction; NYHA 5 New York Heart
Association.
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had a greater increase in exercise duration (p 5 0.013 for
E25 versus placebo, with respective increases of 115 6
[SEM] 36 s vs. 23 6 30 s). For the E50 group the increase
in exercise duration was by 117 6 31 s (p 5 0.003 vs.
placebo). Additionally, the E50 group had a greater (p ,
0.05) improvement in exercise duration compared with
placebo at four weeks (by 80 s, p 5 0.026) and eight weeks
(by 74 s, p 5 0.009) on between-group analysis. At four and
eight weeks the E25 group was not significantly different
from placebo.
On the within-group analysis, the placebo group was sig-
nificantly increased versus baseline at eight weeks (p 5 0.045)
but was not at four and 12 weeks. The E25 group was
significantly (p , 0.05) increased versus baseline at eight and
12 weeks, and the E50 group demonstrated an increase versus
baseline at 4, 8 and 12 weeks. For the time-response analysis,
the placebo group was not increased (p 5 0.23) over the four
time points, but the E25 (p 5 0.0001) and the E50 (p 5
0.0001) groups experienced increases.
On the between-group analysis, the time-response rela-
tionship was statistically significant from placebo for both
the E25 (p 5 0.026) and E50 (p 5 0.016) groups. The
dose-time response was also statistically significant (p 5
0.019).
Figure 2. Last Observation Carried-Forward Analysis.
Table 2. Global Assessment Data
Variable Time Point Treatment
Number of Patients (n, %)
Improved† Unchanged‡ Worse§
Patient Evaluation of Improvement Week 4 Placebo 16 48% 11 33% 6 18%
E25* 23 77% 4 13% 3 10%
E50# 26 70% 7 19% 4 11%
All E* 49 72% 11 16% 7 10%
Week 8 Placebo 15 62% 7 29% 2 8%
E25 18 64% 6 21% 4 14%
E50 22 71% 4 13% 5 16%
All E 40 68% 10 17% 9 15%
Week 12 Placebo 12 60% 6 30% 2 10%
E25 18 75% 3 13% 3 13%
E50 20 77% 3 12% 3 12%
All E 38 76% 6 12% 6 12%
Physician Investigator Evaluation of
Improvement
Week 4 Placebo 15 45% 10 30% 8 24%
E25 19 63% 7 23% 4 13%
E50 22 59% 13 35% 2 5%
All E 41 61% 20 30% 6 9%
Week 8 Placebo 15 62% 7 29% 2 8%
E25 19 68% 5 18% 4 14%
E50 22 71% 5 16% 4 13%
All E 41 69% 10 17% 8 14%
Week 12 Placebo 14 70% 3 15% 3 15%
E25 15 63% 5 21% 4 17%
E50 15 58% 9 35% 2 8%
All E 30 60% 14 28% 6 16%
*Statistically significant (p , 0.05) compared with placebo; #p , 0.10 vs. placebo; †category derived from collapsing the top two,
“Great” and “Marked,” degrees of improvement; ‡category derived by collapsing the 3rd and 4th, “Slight” and “Unchanged,”
degrees of improvement; §last (and worst) of five categories on the Global Assessment instrument.
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Global assessments. As can be observed in Table 2, at
four weeks more subjects in the enoximone-treated groups
were self-assessed as having improved (77% in the E25 and
70% in the E50 groups vs. 48% in the placebo group,
respective p values of 0.019 and 0.055). At week 12 a similar
percentage of enoximone-treated subjects (76%) continued
to assess their status as improved versus 60% of the placebo
patients, which was not statistically significant. In terms of
subjects who considered themselves to have worsened, there
were no differences between the enoximone- (10% to 15%)
and placebo-treated (8% to 18%) subjects at any time point.
There were no statistically significant differences between
the placebo and enoximone groups in the Physician’s
evaluation by Global Assessment (Table 2).
NYHA class, dyspnea scale and diuretic use. There were
no significant changes in NYHA class throughout the study
(Table 3). On the dyspnea scale compared with placebo, the
E25 group contained more subjects with improvement or
less worsening at four weeks (p 5 0.038) and eight weeks
(p 5 0.047) with a trend at 12 weeks (p 5 0.147) but only
in subjects rated at baseline as having no or mild dyspnea.
The same was true for the E50 group (in subjects with no or
mild dyspnea at baseline vs. placebo p 5 0.038 at four
weeks, 0.028 at eight weeks and 0.091 at 12 weeks). In
subjects who were rated as having moderate or severe
dyspnea at baseline, there were no apparent differences
between the placebo and either enoximone-treated group.
The improved dyspnea scale results in enoximone-treated
subjects who had less dyspnea at baseline was not due to
increased diuretic use, as over the course of the study eight
subjects in the E25 group, seven subjects in the E50 group
and seven subjects in the placebo group increased their
diuretic dose by at least 40 mg of furosemide or its
equivalent. There was also no difference in the number of
subjects decreasing diuretic dose (two subjects on placebo,
one on 25 mg three times a day enoximone and three on
50 mg three times a day enoximone).
Holter monitoring. Holter monitoring data available on a
subset of subjects are presented in Table 4. Missing data at
baseline or on follow-up plus the relatively high dropout
rate led to only 29% of subjects in the placebo group having
Holter data available at baseline and at 12 weeks. The active
treatment groups had heart rate data available on 42% (E25)
and 43% (E50) of subjects at baseline and at the end of the
study. For heart rate the only within-group change com-
pared with baseline was a reduction in heart rate in the
placebo group at weeks 4 and 12. There were no statistically
significant changes in heart rate in either enoximone group,
with the E25 group tending to have a decrease and the E50
group being unchanged at 12 weeks. Note that the baseline
Table 3. Change in NYHA Data
Time
Point
Placebo E25 E50
II, n & (%) III, n & (%) II, n & (%) III, n & (%) II, n & (%) III, n & (%)
Imp Wor Imp Wor Imp Wor Imp Wor Imp Wor Imp Wor
4 wks 0 (0) 2 (6) 1 (3) 0 (0) 0 (0) 3 (10) 3 (10) 0 (0) 0 (0) 1 (3) 2 (5) 0 (0)
8 wks 1 (4) 2 (8) 3 (12) 0 (0) 0 (0) 2 (7) 4 (14) 0 (0) 1 (3) 0 (0) 4 (13) 0 (0)
12 wks 1 (5) 1 (5) 4 (20) 0 (0) 1 (4) 0 (0) 2 (8) 0 (0) 2 (8) 0 (0) 4 (15) 1 (4)
Imp 5 n and % improved by $ one class; NYHA 5 New York Heart Association; wor 5 n and % worsened by $ one class.
Table 4. Holter Monitoring Data, Absolute Values and Change From Baseline
Group
Mean Heart Rate
(beats/min) or
Change
PVCs/h or
Change
VT Events/h
or Change
Placebo
Baseline (n 5 17) 89 6 4 125 6 41 0.14 6 0.04
Week 4 (n 5 17), change 23.9 6 1.4# 226 6 53 0.40 6 0.44
Week 12 (n 5 10), change 24.4 6 1.4# 110 6 73 0.09 6 0.04
E25
Baseline (n 5 20) 84 6 2 58 6 19 0.09 6 0.06
Week 4 (n 5 16), change 1.9 6 2.1* 22 6 22 0.02 6 0.11
Week 12 (n 5 14), change 23.0 6 2.1 22 6 10 0.11 6 0.08
E50
Baseline (n 5 22) 88 6 3 130 6 51 0.19 6 0.11
Week 4 (n 5 20), change 1.3 6 1.8* 4 6 56 0.15 6 0.11
Week 12 (n 5 16), change 0.9 6 2.4* 28 6 82 1.29 6 1.01
#p , 0.05 vs. BSL; *p , 0.05 vs. placebo change, Wilcoxon rank sum test.
PVC 5 premature ventricular contraction; VT 5 ventricular tachycardia.
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heart rates tended to be higher in the placebo group than in
the enoximone groups (p 5 0.15), which contributes to a
significant between-group change between the placebo
group and both enoximone groups at four weeks and the
placebo-E50 group at 12 weeks.
There was no effect of either enoximone dose on PVCs/h
or VT events/h. As assessed by the Morganroth criteria
(21), proarrhythmia was present at week 4 or 12 in 35% of
placebo, 45% of the E25 and 41% of the E50 groups (p 5
NS). However, three of four placebo and one of two E25
patients who died did not have follow-up Holters.
Adverse events (AEs). As shown in Table 5, AEs were
reported at a nearly identical rate of 1.71/subject in the
placebo group, 1.67/subject in the E25 group and 1.76/
subject in the E50 group. Both enoximone-treated groups
tended to have fewer numbers of subjects reporting dizzi-
ness, vertigo or hypotension as an AE (p 5 0.05 for the
combined enoximone groups vs. placebo).
Serious AEs were reported in six, three and three patients
in the placebo, E25 and E50 groups, respectively. In
addition, three placebo patients and two E25 patients died
during or within a day of completing the study. A fourth
placebo patient was discontinued in the third treatment
week because of increasing heart failure and died six days
later. There were no deaths in the E50 group (p 5 0.05 vs.
placebo group). Hospitalizations were not different between
groups.
DISCUSSION
The results of this trial indicate that enoximone at doses of
25 mg three times a day and 50 mg three times a day
increases maximal exercise capacity compared with placebo,
as assessed by the protocol-specified method of end point
analysis (last observation carried-forward at 12 weeks). The
favorable effects of enoximone on maximal exercise capacity
appeared to be dose-related, as supported by statistically
significant dose and dose-time-response analyses with the
carry-forward method data set. The improvement in exer-
cise capacity appeared to be accompanied by symptomatic
improvement; both the patients’ and the investigators’
assessments of improvement showed significant effects for
Table 5. Adverse Events by Treatment Group
AE or SAE
Placebo
(n 5 35)
n (%)
E25
(n 5 33)
n (%)
E50
(n 5 37)
n (%)
p Value vs.
Placebo
p Value All
E vs. PE25 E50
Selected AEs*
Chest pain, angina or ischemia 8 (23) 5 (15) 3 (8) 0.54 0.11 0.15
Dizziness, vertigo or hypotension 9 (26) 3 (9) 4 (11) 0.11 0.13 0.05
Fatigue or muscle weakness 5 (14) 2 (6) 4 (11) 0.43 0.73 0.50
Dyspnea 4 (11) 2 (6) 3 (8) 0.67 0.71 0.48
Edema, dependent or peripheral 2 (6) 2 (6) 0 (0) 1.0 0.23 0.60
Cardiac failure 4 (11) 2 (6) 3 (8) 0.67 0.71 0.48
Headache 1 (3) 0 (0) 4 (11) 1.0 0.36 0.66
Rash 3 (9) 1 (3) 1 (3) 0.61 0.35 0.33
Heart rate or rhythm disturbance 6 (17) 5 (15) 8 (22) 1.0 0.77 1.0
Dyspepsia 2 (6) 2 (6) 3 (8) 1.0 1.0 1.0
Abnormal liver function 0 (0) 0 (0) 1 (3) 1.0 1.0 1.0
Diarrhea 2 (6) 7 (21) 6 (16) 0.08 0.26 0.14
Nausea 5 (14) 0 (0) 5 (14) 0.05 1.0 0.30
Vomiting 2 (6) 3 (9) 2 (5) 0.67 1.0 1.0
G.I. bleed 0 ( ) 1 ( ) 0 ( ) 0.49 1.0 1.0
Total AEs (#/subject)* 60 (1.71) 55 (1.67) 65 (1.76) 0.81 0.81 1.0
SAEs*
Cardiac arrest 1 (3) 1 (3) 0 (0) — — —
Severe nausea or vomiting 2 (6) 1 (3) 0 (0) — — —
Severe angina pectoris 1 (3) 0 (0) 0 (0) — — —
Severe abdominal discomfort 1 (3) 0 (0) 0 (0) — — —
Severe fatigue 1 (3) 0 (0) 0 (0) — — —
Renal calculus 0 (0) 1 (3) 0 (0) — — —
Severe dyspnea 0 (0) 0 (0) 1 (3) — — —
TIA 0 (0) 0 (0) 1 (3) — — —
Supraventricular arrhythmia 0 (0) 0 (0) 1 (3) — — —
Total SAEs* 6 (17) 3 (9) 3 (8) 0.48 0.30 0.21
Discontinued for SAE 4 (11) 2 (6) 2 (5) 0.67 0.42 0.44
Discontinued for any AE 8 (23) 4 (12) 5 (14) 0.34 0.37 0.26
All discontinued, AE or other 13 (37) 8 (24) 13 (35) 0.30 1.0 0.51
Deaths 4 (11) 2 (6) 0 (0) 0.67 0.05 0.09
*excluding deaths.
AE 5 adverse events; G.I. 5 gastrointestinal; SAE 5 serious adverse events; TIA 5 transient ischemic attack.
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enoximone 50 mg three times a day at week 4, plus trends
for improvement at other time points and for the 25 mg
three times a day dose. Additionally, subjects treated with
either 25 or 50 mg three times a day had favorable effects on
a dyspnea scale provided that they were only mildly symp-
tomatic at baseline. Enoximone was generally well tolerated,
as both enoximone groups tended to have fewer numbers of
subjects with severe AEs, discontinuations due to AEs and
deaths compared with the placebo group. On limited Holter
monitor data, there was no evidence of increased arrhythmia
in the enoximone-treated patients. These data indicate that
enoximone, given at doses of 25 mg three times a day and
50 mg three times a day, improves exercise capacity without
increasing serious AEs in subjects with class II to III CHF
treated for a 12-week period.
Comparison with previous studies. Heart failure remains
a syndrome characterized by impaired exercise tolerance due
to cardiac contractile and chronotropic dysfunction. Despite
exercise tolerance being the cornerstone of heart failure drug
development from the mid-1980s to the mid-1990s, rela-
tively few placebo-controlled multicenter clinical trials have
demonstrated improved functional capacity in the absence
of evidence for increased adverse effects. The Captopril
Multicenter Study (22), which was the primary basis for that
compound’s approval for a heart failure indication, is the
most obvious example of a successful exercise trial with an
excellent safety profile. Other examples include trials with
lisinopril (23) and quinapril (24). However, many trials did
not detect an increase in exercise capacity by an active agent
compared with placebo (25–28) or documented both an
increase in exercise performance and a trend towards in-
creased AEs (29,30) which were subsequently shown to be
significant (31,32).
Despite the discouraging survival results with positive
inotropic agents (32–37) intermittent or sustained infusions
of outpatient inotropic therapy continues as standard ther-
apy for patients with intractable heart failure (38). This
therapy persists because of cost efficacy compared with
continuous inpatient therapy because it is successful in
palliation of advanced symptoms and also because physi-
cians and patients have accepted the possible trade-off of an
increase in mortality for an improvement in quality of life
(39,40). Oral enoximone has previously been shown to be
efficacious in weaning patients from intravenous inotropic
therapy and as a bridge to cardiac transplant (14). In
addition, low dose enoximone therapy does not appear to
increase mortality in subjects in this study or in other
previous trials (14,16,40). These results indicate that low
dose oral enoximone therapy could be of benefit in
inotrope-dependent patients by allowing them to be weaned
off intravenous therapy and improving exercise capacity and
quality of life. However, this hypothesis will have to be
tested in appropriate placebo-controlled trials conducted in
advanced heart failure patients.
Study limitations. This study is limited by its short dura-
tion, relatively small sample size and—because it was
conducted in the late 1980s—the lack of background ACEI
therapy. Therefore, it is possible that a trial of longer
duration or on different background treatment would yield
different results. However, in a recent trial of low-dose
enoximone used in combination with beta-blockers, most
subjects were also treated with ACEIs, and enoximone
appeared to be beneficial in the presence of full neurohor-
monal blockade (40).
Conclusions. Despite these limitations this trial indicates
that, at low doses, enoximone has the potential to improve
functional capacity in patients with heart failure, without
increasing AEs. Further trials are needed to evaluate the
effects of low-dose enoximone on survival and quality of life
in the setting of current standard medical therapy, particu-
larly in subjects with more advanced heart failure.
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